CTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Other Events
Item 8.01 Other Events.
On December 18, 2018, CTI BioPharma Corp. issued a press release providing a program update following regulatory feedback from the United States Food and Drug Administration on pacritinib development. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit |
Description |
|
99.1 |
Press Release dated December 18, 2018
|
CTI BIOPHARMA CORP Exhibit
EX-99.1 2 ctic-fdatypecfeedbackdec20.htm EXHIBIT 99.1 Exhibit CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development – CTI receives input on key elements of new Phase 3 trial design for patients with myelofibrosis and severe thrombocytopenia — Phase 3 trial of approximately 200 patients expected to begin enrollment in the third quarter of 2019 -SEATTLE,…
To view the full exhibit click here
About CTI BIOPHARMA CORP. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.